Colorado 2024 Regular Session

Colorado House Bill HB1010

Introduced
1/10/24  
Introduced
1/10/24  
Report Pass
2/27/24  
Refer
1/10/24  
Report Pass
2/27/24  
Report Pass
3/8/24  
Refer
2/27/24  
Report Pass
3/8/24  
Engrossed
3/26/24  
Refer
3/8/24  
Engrossed
3/26/24  
Refer
3/26/24  
Report Pass
4/24/24  
Report Pass
4/24/24  
Refer
4/24/24  
Report Pass
4/30/24  
Report Pass
4/30/24  
Enrolled
5/4/24  
Refer
4/30/24  
Enrolled
5/4/24  
Engrossed
5/13/24  
Engrossed
5/13/24  
Enrolled
5/14/24  
Engrossed
5/13/24  
Vetoed
5/17/24  
Enrolled
5/14/24  

Caption

Insurance Coverage for Provider-Administered Drugs

Impact

The enactment of HB 1010 will mark a significant change in the way health benefit plans operate concerning provider-administered medications. By prohibiting insurance carriers from mandating that these drugs be dispensed solely through specific network pharmacies, it allows patients greater freedom in choosing their healthcare providers. This legislation is expected to enhance accessibility for patients needing immediate administration of such medications, ensuring that their treatment is not delayed due to restrictive pharmacy policies.

Summary

House Bill 1010 seeks to modify the insurance coverage framework for provider-administered drugs within the state of Colorado. The bill defines 'provider-administered drugs' as outpatient medications, excluding vaccines, that are typically administered in a healthcare provider's office rather than through self-administration by patients. The main provisions of this bill aim to ease the restrictions imposed by health benefit plans on the dispensing of these medications, especially for treatments related to cancer and other life-threatening conditions.

Sentiment

The sentiment surrounding HB 1010 appears largely supportive, particularly among advocates for patient rights and healthcare accessibility. Many stakeholders applaud the bill for its potential to alleviate bureaucratic barriers that patients face when seeking necessary treatments. However, there are concerns regarding the implications for insurance companies, who may face increased costs and administrative challenges as a result of the changes instituted by this legislation.

Contention

Despite the general support for HB 1010, some points of contention have emerged. Critics raise concerns about the financial implications for insurance carriers and the potential risks associated with less regulated drug administration procedures. Additionally, there is debate regarding the bill's effectiveness in addressing the concerns of patients versus the obligations health insurance providers have in managing costs and care standards. This highlights a complex dynamic between patient needs, provider capabilities, and insurance company policies in the overall healthcare landscape.

Companion Bills

No companion bills found.

Similar Bills

RI S2086

Prohibits healthcare entities from interfering with a patient's right to choose to obtain a clinician-administered drug from their provider or pharmacy of choice.

RI H7365

Provides that health insurers provide coverage for covered clinician-administered drugs under certain circumstances.

RI H5680

Accident And Sickness Insurance Policies

RI S0870

Accident And Sickness Insurance Policies

NJ A797

Limits upfront costs for oral anticancer medications for persons covered under certain health benefits plans.

NJ A2464

Limits upfront costs for oral anticancer medications for persons covered under certain health benefits plans.

RI H8254

Accident And Sickness Insurance Policies

CA AB590

State-funded assistance grants and contracts: advance payments.